Rise Advisors’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $30.5K | Hold |
243
| – | – | 0.01% | 340 |
|
|
2025
Q1 | $26.9K | Sell |
243
-99
| -29% | -$10.9K | 0.01% | 362 |
|
|
2024
Q4 | $46.7K | Sell |
342
-10
| -3% | -$1.37K | 0.02% | 244 |
|
|
2024
Q3 | $40.6K | Hold |
352
| – | – | 0.02% | 296 |
|
|
2024
Q2 | $48.5K | Hold |
352
| – | – | 0.03% | 239 |
|
|
2024
Q1 | $48.5K | Buy |
352
+300
| +577% | +$41.4K | 0.03% | 236 |
|
|
2023
Q4 | $6.85K | Hold |
52
| – | – | ﹤0.01% | 356 |
|
|
2023
Q3 | $5.85K | Sell |
52
-22
| -30% | -$2.48K | ﹤0.01% | 365 |
|
|
2023
Q2 | $6.98K | Sell |
74
-2
| -3% | -$189 | 0.01% | 388 |
|
|
2023
Q1 | $7.69K | Buy |
76
+2
| +3% | +$202 | 0.01% | 400 |
|
|
2022
Q4 | $8.84K | Hold |
74
| – | – | 0.01% | 368 |
|
|
2022
Q3 | $8K | Hold |
74
| – | – | 0.01% | 373 |
|
|
2022
Q2 | $7K | Hold |
74
| – | – | 0.01% | 399 |
|
|
2022
Q1 | $7K | Buy |
74
+21
| +40% | +$1.99K | 0.01% | 375 |
|
|
2021
Q4 | $4.51K | Buy |
+53
| New | +$4.51K | ﹤0.01% | 418 |
|